Trial Profile
Phase II study of induction therapy with subcutaneous bortezomib, oral melphalan and prednisone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary) ; Prednisolone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2013 New trial record